SERPINE1
EmergingSERPINE1/PAI-1 affects clot breakdown and cardiovascular risk; its breast cancer prognostic test role has been largely superseded.
PAI-1 slows down the breakdown of blood clots and is linked to heart disease risk. It also has an older use in breast cancer to help decide who needs chemotherapy, though newer genetic tests have mostly replaced it for that purpose.
SERPINE1 encodes plasminogen activator inhibitor-1 (PAI-1), a protein that inhibits fibrinolysis (clot breakdown) and is also studied as a breast cancer prognostic marker.
Elevated PAI-1 is associated with cardiovascular risk and metabolic syndrome; separately, the uPA/PAI-1 test (measured in breast tumor tissue) is an older, FDA-cleared prognostic test for identifying node-negative breast cancer patients who may or may not benefit from adjuvant chemotherapy.
Measured via tissue-based ELISA for the uPA/PAI-1 oncology test, requiring fresh or frozen tumor tissue (a logistical limitation compared to newer tests); the cardiovascular/metabolic use is measured via standard serum immunoassay.
The uPA/PAI-1 test has been largely overtaken in practice by genomic assays like Oncotype DX and MammaPrint for breast cancer treatment decisions, since these newer tests use more convenient formalin-fixed tissue and provide more detailed genomic risk information.
The uPA/PAI-1 breast cancer test has been overtaken by genomic assays like Oncotype DX and MammaPrint.
- General oncology and cardiology reference literature on PAI-1/SERPINE1 in cardiovascular risk and historical breast cancer prognostic testing (uPA/PAI-1).